Search

everythinglearnresearchcommunity

for

Search:↓

A new compound slows cancer cell growth and causes cell death by blocking cell cycle progression and increasing cell-damaging molecules.

Diphencyprone can cause unexpected and possibly permanent vitiligo.

GLP-1 receptor agonists may help manage and prevent diabetic foot ulcers.

Optimizing the structure of a specific compound greatly improved its effectiveness and precision for treating diabetic complications.

The diphosphonate was the most effective at preventing calcification in rats.

More PDCD4 is linked to obesity, insulin problems, and cell death in ovaries for those with polycystic ovary syndrome.

PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.

RSPO1 could help create new diabetes treatments by increasing pancreatic β cells.

Astilbin can potentially calm overactive immune responses, like in Type 1 Diabetes, by suppressing certain cell activities and reducing inflammation.

Dapagliflozin helps protect heart cells under stress by improving mitochondrial function and reducing cell damage.

Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.

Upadacitinib may effectively treat resistant lichen planopilaris.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

Diphencyprone increases Bcl-2 protein in patients with hair regrowth from alopecia areata.

Pioglitazone may help treat lichen planopilaris, but more research is needed.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

Diphencyprone (DCP) is an effective treatment for severe alopecia areata and resistant warts, with some risks.

New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.

Repaglinide-loaded liponiosomal hybrids improve blood sugar control and insulin release better than regular Repaglinide.

20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.

P-3074 effectively blocks scalp DHT better than oral finasteride.

Finasteride reduces movement issues in Parkinson's disease rats.

Changing the 6-position on benzopyran molecules affects insulin release, with some compounds showing strong inhibitory effects.

Pegylated interferon-alpha 2a can cause a rare nerve disorder, but early treatment can lead to full recovery.

A new compound, HTPI, promotes hair growth by protecting cells from damage and regulating energy use.

Dracorhodin perchlorate helps heal wounds in diabetic rats by reducing inflammation.

A protein called sFRP4 from skin cells stops the development of pigment-producing cells in hair.

Dystonia may be part of PAS-4 and linked to immune issues.